Sean I Savitz

Summary

Affiliation: Texas Medical Center
Country: USA

Publications

  1. pmc Nitric oxide facilitates delivery and mediates improved outcome of autologous bone marrow mononuclear cells in a rodent stroke model
    Mallikarjunarao Kasam
    Department of Neurology, Stroke Team, The University of Texas Houston Medical School, Houston, Texas, United States of America
    PLoS ONE 7:e32793. 2012
  2. pmc Heat stress presenting with encephalopathy and MRI findings of diffuse cerebral injury and hemorrhage
    Waldo R Guerrero
    Department of Neurology, University of Texas Medical School Houston, UT Health, Houston, TX, USA
    BMC Neurol 13:63. 2013
  3. doi request reprint Changing demographics at a comprehensive stroke center amidst the rise in primary stroke centers
    Karen C Albright
    Health Services and Outcomes Research Center for Outcome and Effectiveness Research and Education, School of Public Health, Department of Epidemiology, School of Medicine, University of Alabama atBirmingham, Birmingham, AL, USA
    Stroke 44:1117-23. 2013
  4. doi request reprint Thunderclap headache with normal CT and lumbar puncture: further investigations are unnecessary: for
    Sean I Savitz
    University of Texas Houston Medical School, Department of Neurology, 6431 Fannin Street, Houston, TX 77030, USA
    Stroke 39:1392-3. 2008
  5. doi request reprint Identifying patients at high risk for poor outcome after intra-arterial therapy for acute ischemic stroke
    Hen Hallevi
    Department of Neurology, University of Texas Health Science Center at Houston, Houston, TX 77030, USA
    Stroke 40:1780-5. 2009
  6. doi request reprint A Critique of SAINT II: wishful thinking, dashed hopes, and the future of neuroprotection for acute stroke
    Sean I Savitz
    Department of Neurology, University of Texas, Houston Medical School, Houston, Texas, USA
    Stroke 39:1389-91. 2008
  7. doi request reprint Stem Cell Therapy as an Emerging Paradigm for Stroke (STEPS) II
    Sean I Savitz
    Department of Neurology, University of Texas Medical School at Houston, Houston, TX 77030, USA
    Stroke 42:825-9. 2011
  8. doi request reprint Stem cells and stroke: are we further away than anyone is willing to admit?
    Sean I Savitz
    Department of Neurology, University of Texas Medical School at Houston, 6431 Fannin Street, Houston, TX 77030, USA
    Int J Stroke 7:34-5. 2012
  9. doi request reprint Intravenous autologous bone marrow mononuclear cells for ischemic stroke
    Sean I Savitz
    Department of Neurology, University of Texas Medical School at Houston, Houston, TX, USA
    Ann Neurol 70:59-69. 2011
  10. ncbi request reprint Outcome analysis in clinical trial design for acute stroke: physicians' attitudes and choices
    Sean I Savitz
    Department of Neurology, University of Texas Houston Medical School, Houston, TX 77030, USA
    Cerebrovasc Dis 26:156-62. 2008

Detail Information

Publications72

  1. pmc Nitric oxide facilitates delivery and mediates improved outcome of autologous bone marrow mononuclear cells in a rodent stroke model
    Mallikarjunarao Kasam
    Department of Neurology, Stroke Team, The University of Texas Houston Medical School, Houston, Texas, United States of America
    PLoS ONE 7:e32793. 2012
    ..The objective of this study was to determine the relevance of vasoactive mediators, generated in response to MNC injection, as factors regulating cerebral perfusion (CP), the biodistribution of MNC, and outcome in stroke...
  2. pmc Heat stress presenting with encephalopathy and MRI findings of diffuse cerebral injury and hemorrhage
    Waldo R Guerrero
    Department of Neurology, University of Texas Medical School Houston, UT Health, Houston, TX, USA
    BMC Neurol 13:63. 2013
    ..Heat stress results in multiorgan failure and CNS injury. There a few case reports in the literature on the neurological consequences of heat stress...
  3. doi request reprint Changing demographics at a comprehensive stroke center amidst the rise in primary stroke centers
    Karen C Albright
    Health Services and Outcomes Research Center for Outcome and Effectiveness Research and Education, School of Public Health, Department of Epidemiology, School of Medicine, University of Alabama atBirmingham, Birmingham, AL, USA
    Stroke 44:1117-23. 2013
    ..We hypothesized that the rise in PSCs in the Houston area was associated with demographic changes and decreased trial enrollment at our comprehensive stroke center...
  4. doi request reprint Thunderclap headache with normal CT and lumbar puncture: further investigations are unnecessary: for
    Sean I Savitz
    University of Texas Houston Medical School, Department of Neurology, 6431 Fannin Street, Houston, TX 77030, USA
    Stroke 39:1392-3. 2008
  5. doi request reprint Identifying patients at high risk for poor outcome after intra-arterial therapy for acute ischemic stroke
    Hen Hallevi
    Department of Neurology, University of Texas Health Science Center at Houston, Houston, TX 77030, USA
    Stroke 40:1780-5. 2009
    ..Despite high rates of recanalization, the outcome is variable. We attempted to identify predictors of outcome that will enable better patient selection for IAT...
  6. doi request reprint A Critique of SAINT II: wishful thinking, dashed hopes, and the future of neuroprotection for acute stroke
    Sean I Savitz
    Department of Neurology, University of Texas, Houston Medical School, Houston, Texas, USA
    Stroke 39:1389-91. 2008
  7. doi request reprint Stem Cell Therapy as an Emerging Paradigm for Stroke (STEPS) II
    Sean I Savitz
    Department of Neurology, University of Texas Medical School at Houston, Houston, TX 77030, USA
    Stroke 42:825-9. 2011
    ....
  8. doi request reprint Stem cells and stroke: are we further away than anyone is willing to admit?
    Sean I Savitz
    Department of Neurology, University of Texas Medical School at Houston, 6431 Fannin Street, Houston, TX 77030, USA
    Int J Stroke 7:34-5. 2012
    ..We are at least 5-10 years away from knowing if cell therapies will improve clinical outcome in stroke patients. The use of stem cells in stroke therapy remains investigational only...
  9. doi request reprint Intravenous autologous bone marrow mononuclear cells for ischemic stroke
    Sean I Savitz
    Department of Neurology, University of Texas Medical School at Houston, Houston, TX, USA
    Ann Neurol 70:59-69. 2011
    ..Mononuclear cells (MNCs) from the bone marrow reduce neurological deficits in animal stroke models. We determined if autologous MNC infusion was feasible and safe in patients with ischemic stroke...
  10. ncbi request reprint Outcome analysis in clinical trial design for acute stroke: physicians' attitudes and choices
    Sean I Savitz
    Department of Neurology, University of Texas Houston Medical School, Houston, TX 77030, USA
    Cerebrovasc Dis 26:156-62. 2008
    ..Recent studies have introduced more sensitive outcome measures such as the shift analysis to detect a treatment effect in AIS trials and are also including imaging as a surrogate of injury...
  11. pmc Pooled analysis of patients with thunderclap headache evaluated by CT and LP: is angiography necessary in patients with negative evaluations?
    Sean I Savitz
    Department of Neurology, University of Texas Houston Medical School, Houston, TX 77030, USA
    J Neurol Sci 276:123-5. 2009
    ..Some have suggested that angiography is also indicated in this common clinical situation. Is evaluation with brain CT and LP for thunderclap headache to rule out SAH sufficient and is angiography needed?..
  12. ncbi request reprint Shift analysis versus dichotomization of the modified Rankin scale outcome scores in the NINDS and ECASS-II trials
    Sean I Savitz
    Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    Stroke 38:3205-12. 2007
    ..The SAINT I trial that showed a significant benefit of the neuroprotectant NXY-059 used a novel outcome for acute ischemic stroke trials: a shift toward good functional outcome on the 7-category modified Rankin scale (mRS)...
  13. pmc Increased blood-brain barrier permeability on perfusion CT might predict malignant middle cerebral artery infarction
    Hesna Bektas
    Department of Neurology, The University of Texas Houston Medical School, Houston, TX 77030, USA
    Stroke 41:2539-44. 2010
    ..The purpose of this study was to determine the predictive value of blood-brain barrier permeability measured using perfusion CT for development of malignant middle cerebral artery infarction requiring hemicraniectomy (HC)...
  14. pmc Functional assessments in the rodent stroke model
    Krystal L Schaar
    University of Texas Medical School at Houston, Department of Neurology, 6431 Fannin Houston, TX 77030, USA
    Exp Transl Stroke Med 2:13. 2010
    ..While there is no perfect test, there are many assessments that are sensitive to detecting the array of impairments, from global to modality specific, after stroke...
  15. doi request reprint Necroptosis, a novel form of caspase-independent cell death, contributes to neuronal damage in a retinal ischemia-reperfusion injury model
    Daniel M Rosenbaum
    Department of Neurology, SUNY Downstate Medical Center, Brooklyn, New York, USA
    J Neurosci Res 88:1569-76. 2010
    ..Conclusion: Necroptosis is an important mode of neuronal cell death and involves autophagy in a model of retinal ischemia...
  16. pmc Thrombolytic therapy for patients who wake-up with stroke
    Andrew D Barreto
    Stroke Division, Department of Neurology, University of Texas Houston Medical School, Houston, USA
    Stroke 40:827-32. 2009
    ..The purpose of this study was to describe our center's experience with off-label, compassionate thrombolysis for wake-up stroke (WUS) patients...
  17. pmc Bone marrow mononuclear cells protect neurons and modulate microglia in cell culture models of ischemic stroke
    Sushil Sharma
    Department of Neurology, University of Texas Medical School at Houston, Houston, Texas 77030, USA
    J Neurosci Res 88:2869-76. 2010
    ..MNCs provide broad neuroprotection against a variety of injuries relevant to stroke...
  18. ncbi request reprint CLOTBUST-Hands Free: pilot safety study of a novel operator-independent ultrasound device in patients with acute ischemic stroke
    Andrew D Barreto
    From the Department of Neurology, Stroke Program A D B, L S, A W B, P S, H I, N R G, S I S, J C G and Center for Clinical and Translational Sciences H P, M A H, R P, M H R, University of Texas Health Science Center at Houston, TX Comprehensive Stroke Center, Department of Neurology, The University of Alabama at Birmingham A V A, A S and Department of Neurology, Dresden University Stroke Center, University of Technology Dresden, Dresden, Germany K B
    Stroke 44:3376-81. 2013
    ....
  19. pmc Does study enrollment delay treatment with intravenous thrombolytics for acute ischemic stroke?
    Sheryl Martin-Schild
    Department of Neurology, University of Texas Medical SchoolHouston Medical School, Houston, Texas 77030, USA
    Stroke 40:663. 2009
    ..Enrollment in acute stroke trials at a stroke center with multiple study protocols may delay the initiation of intravenous thrombolytics in patients who present within 3 hours of symptom onset...
  20. doi request reprint Recovery after ischemic stroke: criteria for good outcome by level of disability at day 7
    Hen Hallevi
    Department of Neurology, Vascular Neurology Program, University of Texas at Houston Health Science Center, Houston, Texas 77030, USA
    Cerebrovasc Dis 28:341-8. 2009
    ..Ischemic stroke is a leading cause of morbidity. Assessing the chances of recovery is critical to optimize poststroke care...
  21. pmc Thrombus burden is associated with clinical outcome after intra-arterial therapy for acute ischemic stroke
    Andrew D Barreto
    Department of Neurology, Stroke Division, University of Texas, Houston Health Science Center, Houston, TX 77030, USA
    Stroke 39:3231-5. 2008
    ..The aim of the study was to determine the impact of intra-arterial thrombus burden on intra-arterial treatment (IAT) and clinical outcome...
  22. pmc Therapeutic time window and dose response of autologous bone marrow mononuclear cells for ischemic stroke
    Bing Yang
    Department of Neurology, University of Texas Medical School at Houston, Houston, TX 77030, USA
    J Neurosci Res 89:833-9. 2011
    ..In conclusion, we found a maximum reduction in neurological deficits at 10 and 30 million cells/kg and a therapeutic time window up to 72 hr after stroke. © 2011 Wiley-Liss, Inc...
  23. pmc Combined neuroprotective modalities coupled with thrombolysis in acute ischemic stroke: a pilot study of caffeinol and mild hypothermia
    Sheryl Martin-Schild
    Department of Neurology, University of Texas Houston Medical School, Houston, TX, USA
    J Stroke Cerebrovasc Dis 18:86-96. 2009
    ..We tested whether combining caffeinol and hypothermia with tissue plasminogen activator (t-PA) in patients with acute stroke is safe and feasible...
  24. pmc Is the drip-and-ship approach to delivering thrombolysis for acute ischemic stroke safe?
    Sheryl Martin-Schild
    Department of Neurology, University of Texas Houston Health Science Center, Houston, Texas, USA
    J Emerg Med 41:135-41. 2011
    ..The drip-and-ship method of treating stroke patients may increase the use of tissue plasminogen activator (t-PA) in community hospitals...
  25. doi request reprint IL-10 directly protects cortical neurons by activating PI-3 kinase and STAT-3 pathways
    Sushil Sharma
    Department of Neurology, Stroke Program, University of Texas Medical School at Houston, Houston, TX 77030, USA
    Brain Res 1373:189-94. 2011
    ..These data suggest that IL-10 provides neuroprotection by acting via IL-10 receptor and PI3K/AKT and STAT-3 signal transduction pathways...
  26. pmc Autologous bone marrow mononuclear cells enhance recovery after acute ischemic stroke in young and middle-aged rats
    Miranda Brenneman
    Department ofNeurology, University of Texas, Houston Medical School, Houston, Texas 77030, USA
    J Cereb Blood Flow Metab 30:140-9. 2010
    ..Autologous bone marrow MNCs can be safely harvested from rodents after stroke, migrate to the peri-infarct area, enhance recovery, and modulate the post-ischemic inflammatory response...
  27. doi request reprint The complications of cardioembolic stroke: lessons from the VISTA database
    Hen Hallevi
    University of Texas at Houston, Vascular Neurology Program, Houston, Tex 77030, USA
    Cerebrovasc Dis 26:38-40. 2008
    ..Cardioembolic stroke (CES) accounts for 20-30% of ischemic strokes. We attempted to describe the complications of CES...
  28. pmc Pharmacological deep vein thrombosis prophylaxis does not lead to hematoma expansion in intracerebral hemorrhage with intraventricular extension
    Tzu Ching Wu
    Department of Neurology, The University of Texas Houston Medical School, 6431 Fannin Street Suite, Houston, TX 77030, USA
    Stroke 42:705-9. 2011
    ..However, insufficient data exist on hematoma volume in patients with ICH before and after pharmacological deep venous thrombosis prophylaxis, leaving physicians with uncertainty regarding the safety of this practice...
  29. pmc Safety of eptifibatide for subcortical stroke progression
    Sheryl Martin-Schild
    Department of Neurology, University of Texas Houston Medical School, Houston, TX, USA
    Cerebrovasc Dis 28:595-600. 2009
    ..There is no proven treatment for stroke progression in patients with subcortical infarcts. Eptifibatide, a glycoprotein IIb/IIIa inhibitor, might halt stroke progression by improving flow in the microcirculation...
  30. pmc Anticoagulation after cardioembolic stroke: to bridge or not to bridge?
    Hen Hallevi
    Department of Neurology, University of Texas Health Science Center at Houston, 6431 Fannin St, MSB 7 044, Houston, TX 77030, USA
    Arch Neurol 65:1169-73. 2008
    ..Outcome measures and adverse events were collected prospectively. Laboratory values were captured from the records...
  31. pmc Aggressive blood pressure-lowering treatment before intravenous tissue plasminogen activator therapy in acute ischemic stroke
    Sheryl Martin-Schild
    Vascular Neurology Program, Department of Neurology, University of Texas Health Science Center at Houston, 6431 Fannin St, Medical School Bldg Room 7 128, Houston, TX 77030, USA
    Arch Neurol 65:1174-8. 2008
    ..We evaluated the effect of elevated BP and its management on clinical outcomes after tPA therapy in AIS...
  32. pmc The IVH score: a novel tool for estimating intraventricular hemorrhage volume: clinical and research implications
    Hen Hallevi
    Department of Neurology, University of Texas Health Science Center at Houston, Houston, TX, USA
    Crit Care Med 37:969-74, e1. 2009
    ..Intraventricular extension of intracerebral hemorrhage (IVH) is an independent predictor of poor outcome. IVH volume may be important in outcome prediction and management; however, it is difficult to measure routinely...
  33. doi request reprint Methodological quality of animal studies of neuroprotective agents currently in phase II/III acute ischemic stroke trials
    Maria Philip
    Department of Neurology, University of Texas Houston Medical School, Houston, TX 77030, USA
    Stroke 40:577-81. 2009
    ..We analyzed the quality and adequacy of animal studies supporting the efficacy of NXY-059 and other neuroprotective agents that are currently being investigated in phase II/III trials...
  34. ncbi request reprint Future of neuroprotection for acute stroke: in the aftermath of the SAINT trials
    Sean I Savitz
    Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Ann Neurol 61:396-402. 2007
    ..We discuss new suggestions to bridge the chasm between preclinical animal modeling and acute human stroke trials to potentially enhance the future assessment of novel neuroprotective drugs...
  35. pmc Intracerebral hemorrhage in cocaine users
    Sheryl Martin-Schild
    Department of Neurology, Tulane University, New Orleans, LA, USA
    Stroke 41:680-4. 2010
    ..Cocaine is a cause of intracerebral hemorrhage (ICH), but there are no large studies that have characterized the location, pathology, and outcome of patients with cocaine-associated ICH...
  36. pmc Ischemic stroke may activate bone marrow mononuclear cells to enhance recovery after stroke
    Bing Yang
    Department of Neurology, University of Texas Medical School at Houston, UT Health, Houston, TX, USA
    Stem Cells Dev 21:3332-40. 2012
    ..Autologous MNCs exert different biological responses when derived from the poststroke setting compared with normal animals...
  37. pmc The argatroban and tissue-type plasminogen activator stroke study: final results of a pilot safety study
    Andrew D Barreto
    Department of Neurology, University of Texas Houston Medical School, Houston, TX, USA
    Stroke 43:770-5. 2012
    ..The Argatroban tPA Stroke Study was an open-label, pilot safety study of tPA plus Argatroban in patients with ischemic stroke due to proximal intracranial occlusion...
  38. doi request reprint Deleterious role of TNF-alpha in retinal ischemia-reperfusion injury
    Samuel Berger
    Department of Neurology, SUNY Downstate Medical Center, Brooklyn, New York11203, USA
    Invest Ophthalmol Vis Sci 49:3605-10. 2008
    ..This study was conducted to further elucidate the role of TNF-alpha and its receptor in an in vivo model of retinal ischemia-reperfusion injury by investigating its effects on retinal histopathology and function...
  39. pmc The University of Texas Houston Stroke Registry (UTHSR): implementation of enhanced data quality assurance procedures improves data quality
    Mohammad H Rahbar
    Division of Epidemiology, Human Genetics, and Environmental Sciences, The University of Texas School of Public Health at Houston, Houston, TX 77030, USA
    BMC Neurol 13:61. 2013
    ..We share our experience regarding the establishment of enhanced QA procedures for the University of Texas Houston Stroke Registry (UTHSR) and evaluate whether these QA procedures have improved data quality in UTHSR...
  40. pmc Challenges enrolling patients with acute ischemic stroke into cell therapy trials
    Farhaan S Vahidy
    Vascular Neurology Program, Department of Neurology, University of Texas Medical School, Houston 77030, Texas, USA
    Stem Cells Dev 22:27-30. 2013
    ..In this article, we discuss practical barriers and challenges encountered during the trial and provide lessons learned for the design and planning of future clinical trials testing novel cell therapies for acute ischemic stroke...
  41. pmc Cell therapy for stroke
    Sean I Savitz
    Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
    NeuroRx 1:406-14. 2004
    ..We emphasize the current, limited knowledge about the biology of implant sources and discuss special conditions in stroke that will impact the potential success of neurotransplantation in clinical trials...
  42. pmc Effect of needle diameter and flow rate on rat and human mesenchymal stromal cell characterization and viability
    Peter A Walker
    Department of Pediatric Surgery, University of Texas Medical School at Houston, Houston, Texas 77030, USA
    Tissue Eng Part C Methods 16:989-97. 2010
    ..We hypothesize that injection of rat and human MSCs through various clinically relevant-sized catheters and flow rates will not affect cell viability, characterization, or function...
  43. ncbi request reprint Prophylactic neuroprotection
    Sean I Savitz
    Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
    Curr Drug Targets 8:846-9. 2007
    ..This review will focus on which target populations should be considered for prophylactic neuroprotection trials and which drugs might be used in such trials...
  44. pmc Stroke Therapy Academic Industry Roundtable (STAIR) recommendations for extended window acute stroke therapy trials
    Jeffrey L Saver
    Department of Neurology, Geffen School of Medicine, UCLA, Los Angeles, CA, USA
    Stroke 40:2594-600. 2009
    ..a. thrombolysis or devices may be acceptable. Statistical considerations and definitions of successful recanalization/reperfusion are suggested for these trials...
  45. doi request reprint Design of a prospective, dose-escalation study evaluating the Safety of Pioglitazone for Hematoma Resolution in Intracerebral Hemorrhage (SHRINC)
    Nicole R Gonzales
    Department of Neurology, UT Health, University of Texas Medical School Houston, TX 77030, USA
    Int J Stroke 8:388-96. 2013
    ..Clinical outcomes are measured by the National Institutes of Health Stroke Scale (NIHSS), the Barthel Index, modified Rankin Scale, Stroke Impact Scale-16, and EuroQol at three- and six-months...
  46. doi request reprint Current practice versus willingness to enroll in clinical trials: paradox among vascular neurologists about treatment for acute ischemic stroke
    Ramy El Khoury
    Department of Neurology, University of Texas in Houston, Houston, Texas 77030, USA
    Stroke 41:2038-43. 2010
    ..Clinical trials are assessing the efficacy of fibrinolysis in extended time windows for acute ischemic stroke...
  47. ncbi request reprint Neurotransplantation of fetal porcine cells in patients with basal ganglia infarcts: a preliminary safety and feasibility study
    Sean I Savitz
    Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass 02215, USA
    Cerebrovasc Dis 20:101-7. 2005
    ..Cell transplantation is safe in animal models and enhances recovery from stroke in rats...
  48. pmc Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect
    Uwe M Fischer
    Department of Pediatric Surgery, University of Texas Medical School at Houston, 6431 Fannin Street, Houston, TX 77030, USA
    Stem Cells Dev 18:683-92. 2009
    ..Larger stem and progenitor cells are initially trapped inside the lungs following intravenous administration with a therapeutically questionable number of cells reaching the arterial system acutely...
  49. ncbi request reprint A critical appraisal of the NXY-059 neuroprotection studies for acute stroke: a need for more rigorous testing of neuroprotective agents in animal models of stroke
    Sean I Savitz
    Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Palmer 127, Boston, MA 02215, USA
    Exp Neurol 205:20-5. 2007
    ..Future neuroprotective agents need more rigorous testing in animal models of focal cerebral ischemia and appropriate evaluation in clinical studies that better match the preclinical data...
  50. ncbi request reprint Bone marrow-derived mononuclear cell populations in pediatric and adult patients
    Matthew T Harting
    Department of Pediatric Surgery, University of Texas Medical School at Houston, Houston, Texas, USA
    Cytotherapy 11:480-4. 2009
    ..Concern has been raised that autologous MNC derived from elderly patients may be less effective as a therapeutic option...
  51. doi request reprint Diagnosis and initial management of cerebellar infarction
    Jonathan A Edlow
    Department of Emergency Medicine, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, MA 02215, USA
    Lancet Neurol 7:951-64. 2008
    ..Here, we review the clinical presentation of cerebellar infarction, from diagnosis and misdiagnosis to patients' monitoring, treatment, and potential complications...
  52. doi request reprint Clotting factors to treat thrombolysis-related symptomatic intracranial hemorrhage in acute ischemic stroke
    Yazan J Alderazi
    Department of Neurology, University of Texas Health Science Center at Houston, Houston, Texas Electronic address
    J Stroke Cerebrovasc Dis 23:e207-14. 2014
    ..Symptomatic intracranial hemorrhage (sICH) occurs uncommonly after ischemic stroke therapy with tissue plasminogen activator (tPA). Clotting factor administration may be a treatment option...
  53. pmc No consensus on definition criteria for stroke registry common data elements
    Karen C Albright
    Department of Neurology, University of Alabama at Birmingham, Birmingham, Ala, USA
    Cerebrovasc Dis Extra 1:84-92. 2011
    ....
  54. ncbi request reprint EDG receptors as a potential therapeutic target in retinal ischemia-reperfusion injury
    Sean I Savitz
    Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, USA
    Brain Res 1118:168-75. 2006
    ..These results suggest that LPA receptor signaling may play an important role in neuroprotection in retinal ischemia-reperfusion injury...
  55. pmc Update of the stroke therapy academic industry roundtable preclinical recommendations
    Marc Fisher
    Department of Neurology, University of Massachusetts Medical School, Worcester, MA 01605, USA
    Stroke 40:2244-50. 2009
    ..Although the recommendations cannot be validated until effective therapies based on them emerge from clinical trials, it is hoped that adherence to them might enhance the chances for success...
  56. pmc Intra-arterial delivery of cell therapies for stroke
    Vivek Misra
    Department of Neurology, University of Texas Medical School at Houston, UT Health, Houston, TX 77030, USA
    Stem Cells Dev 21:1007-15. 2012
    ..This article reviews the trial methodology and procedural details of these studies and discusses the rationale and challenges in designing IA cell therapy trials for ischemic stroke...
  57. ncbi request reprint Arterial occlusive lesions recanalize more frequently in women than in men after intravenous tissue plasminogen activator administration for acute stroke
    Sean I Savitz
    Division of Cerebrovascular Disease, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Ave, Palmer 127, Boston, MA 02215, USA
    Stroke 36:1447-51. 2005
    ..Coagulation and fibrinolysis differ between sexes. These findings prompted us to investigate possible gender differences in arterial recanalization after intravenous tissue plasminogen activator (IV tPA)...
  58. ncbi request reprint Vertebrobasilar disease
    Sean I Savitz
    Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    N Engl J Med 352:2618-26. 2005
  59. ncbi request reprint Pitfalls in the diagnosis of cerebellar infarction
    Sean I Savitz
    Departments of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    Acad Emerg Med 14:63-8. 2007
    ..Cerebellar infarctions are an important cause of neurologic disease. Failure to recognize and rapidly diagnose cerebellar infarction may lead to serious morbidity and mortality due to hydrocephalus and brain stem infarction...
  60. pmc Progenitor cell therapy for the treatment of central nervous system injury: a review of the state of current clinical trials
    Peter A Walker
    Department of Surgery, Medical School at Houston, University of Texas, 6431 Fannin Street, MSB 5 236, Houston, TX 77030, USA
    Stem Cells Int 2010:369578. 2010
    ....
  61. ncbi request reprint CTP infarct core may predict poor outcome in stroke patients treated with IV t-PA
    Tzu Ching Wu
    Department of Neurology, University of Texas Houston Medical School, Houston, TX, USA Electronic address
    J Neurol Sci 340:165-9. 2014
    ..We reviewed CTP data in AIS patients treated with IV t-PA to uncover potential predictors of clinical outcome...
  62. ncbi request reprint Ischemic preconditioning is mediated by erythropoietin through PI-3 kinase signaling in an animal model of transient ischemic attack
    Samit Malhotra
    Department of Neurology, Albert Einstein College of Medicine, Bronx, New York, USA
    J Neurosci Res 83:19-27. 2006
    ..05). Pretreatment with the PI-3 kinase inhibitor wortmannin abolished the protective effect of IP against ischemic injury (P < 0.05). IP may be mediated in part by EPO through a PI-3 kinase pathway...
  63. doi request reprint Predicting the need for hospital admission of TIA patients
    Indrani Acosta
    University of Texas at Houston Stroke Center, Houston, TX, United States
    J Neurol Sci 336:83-6. 2014
    ..It is unknown which patient will benefit most from hospital admission after transient ischemic attack (TIA). Our aim was to define predictors of a positive hospital outcome...
  64. ncbi request reprint Vertebral artery compression of the medulla
    Sean I Savitz
    Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass 02215, USA
    Arch Neurol 63:234-41. 2006
    ..Much less is known about vertebral artery compression of the medulla...
  65. pmc Investigational therapies for ischemic stroke: neuroprotection and neurorecovery
    Preeti Sahota
    Department of Neurology, University of Texas Medical School at Houston, Houston, TX 77030, USA
    Neurotherapeutics 8:434-51. 2011
    ..In this review, we highlight select pharmacologic and cell-based therapies that are currently in the clinical trial stage for stroke...
  66. pmc Necrostatin-1 reduces histopathology and improves functional outcome after controlled cortical impact in mice
    Zerong You
    Neuroscience Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts 02129, USA
    J Cereb Blood Flow Metab 28:1564-73. 2008
    ..The data suggest that necroptosis plays a significant role in the pathogenesis of cell death and functional outcome after TBI and that necrostatin-1 may have therapeutic potential for patients with TBI...
  67. pmc Linking Notch signaling to ischemic stroke
    Joseph F Arboleda-Velasquez
    Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 105:4856-61. 2008
    ....
  68. ncbi request reprint Cell transplantation for stroke
    Sean I Savitz
    Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
    Ann Neurol 52:266-75. 2002
    ..The survival, integration, and efficacy of neural transplants in stroke patients will depend on the type, severity, chronicity, adequacy of circulation, and location of the stroke lesion...
  69. pmc Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury
    Anna K Junk
    Department of Neurology, Albert Einstein College of Medicine, Bronx, NY 10461, USA
    Proc Natl Acad Sci U S A 99:10659-64. 2002
    ..These results further establish EPO as a neuroprotective agent in acute neuronal ischemic injury...
  70. ncbi request reprint NXY-059 for the treatment of stroke
    Sean I Savitz
    N Engl J Med 357:2198; author reply 2198-9. 2007
  71. pmc Telemedicine is crucial to implementing acute stroke therapy
    Sean I Savitz
    MedGenMed 8:39. 2006
  72. ncbi request reprint Neuroprotective effects of prostaglandin A(1) in rat models of permanent focal cerebral ischemia are associated with nuclear factor-kappaB inhibition and peroxisome proliferator-activated receptor-gamma up-regulation
    Hui Ling Zhang
    Department of Pharmacology and Laboratory of Aging and Nervous Diseases, Soochow University School of Medicine, Suzhou, China
    J Neurosci Res 86:1132-41. 2008
    ..These findings suggest that PGA(1)-mediated neuroprotective effect against ischemia appears to be associated with blocking NF-kappaB activation and likely with up-regulating PPAR-gamma expression...